How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution.
- Author:
Bhumsuk KEAM
1
;
Dong Wan KIM
;
Jin Hyun PARK
;
Jeong Ok LEE
;
Tae Min KIM
;
Se Hoon LEE
;
Doo Hyun CHUNG
;
Dae Seog HEO
Author Information
1. Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. kimdw@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Gefitinib;
EGFR mutation;
Trend;
Lung neoplasms
- MeSH:
Carcinoma, Non-Small-Cell Lung;
Disease-Free Survival;
Humans;
Lung;
Lung Neoplasms;
Prescriptions;
Quinazolines;
Receptor, Epidermal Growth Factor;
Retrospective Studies
- From:Cancer Research and Treatment
2013;45(3):178-185
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Gefitinib was introduced in 2002 for treatment of non-small cell lung cancer (NSCLC); however, it is not clear whether its use in daily practice has changed the outcome of patients. The purpose of this study is to evaluate the question of how molecular understanding regarding gefitinib and epidermal growth factor receptor (EGFR) mutation affect the prescribing patterns and clinical outcomes of treatment with gefitinib in NSCLC, in a real practical field. MATERIALS AND METHODS: We conducted a retrospective analysis of the consecutive database of NSCLC patients who were treated with gefitinib at Seoul National University Hospital between January 2002 and December 2011. Prescribing patterns and clinical outcomes were analyzed by year. RESULTS: A total of 1,115 NSCLC patients, who received gefitinib at recurred or metastatic setting, were included in this study. Proportion of patients receiving gefitinib, for the first line, showed a gradual increase, from 5.2% in 2002-2003 to 30.6% in 2010-2011. Proportion of patients who underwent EGFR mutation testing showed a rapid increase, from 0.6% in 2004-2005 to 73.5% in 2010-2011. The response rate also showed a gradual increase, from 17.2% in 2002-2003 to 57.1% in 2010-2011 (p<0.001). The median progression-free survival of gefitinib was increased with statistical significance from 2.8 months in 2002-2003 to 9.1 months in 2010-2011 (p<0.001). CONCLUSION: We demonstrated that molecular understanding and practical use of EGFR mutation testing have resulted in a change in the prescription patterns of gefitinib. Use of an enrichment strategy can lead to improvement in the efficacy of gefitinib in real practice.
